Project Medtech

The episode is dominated by personal narrative for roughly half its runtime, with actionable B2B insights concentrated in the second half. Specific NHS economic data and the stakeholder-mapping approach are genuinely useful, but the final business advice is generic and the host adds little analytical pressure to extract deeper insights.

“at 50% adoption across just England, it would save 11.2 million pounds each year, free up 12,000 gynecology surgery slots and reduce emergency department admissions by 10,000”

“a third of patients who are experiencing miscarriage will attend A and E, and I think it's one fifth of those patients are immediately discharged”

The parliamentary escalation strategy and the geographic patient-advocacy tactic (Edinburgh patients demanding what Glasgow has) are genuinely fresh go-to-market moves rarely discussed in medtech. The closing business advice, however, defaults to the well-worn 'focus on the problem not the solution' cliché.

“together we raised a motion in Parliament, um, we got some signatures from other members of Parliament to support it and it got debated in the Houses of Parliament last, last November”

“now people who are based in Edinburgh have been advocating to the hospital, hey, it's available in Glasgow. Why is it available to these people and not, not to me?”

Laura is a genuine practitioner-founder with NHS operational background who invented, patented, and commercially deployed a Class 1 medical device achieving NHS procurement within six weeks of outreach - real traction at real scale. She is an early-stage founder rather than a seasoned multi-exit operator, which caps the score.

“within six weeks, the NHS bought the Miscarriage Collection Cradle, which is absolutely rapid”

“it's now being used in 28 NHS hospitals, seven hospitals across Europe and in seven countries in universities”

The episode is notably concrete: named NHS trust adoption figures, specific pound-savings projections, surgical slot and ED admission reductions, collection rates, and a named Glasgow trial site all appear. Some vagueness around the US market strategy and insurance pathway slightly dilutes an otherwise evidence-rich episode.

“at 50% adoption across just England, it would save 11.2 million pounds each year, free up 12,000 gynecology surgery slots and reduce emergency department admissions by 10,000”

“within six weeks, the NHS bought the Miscarriage Collection Cradle”

The host is emotionally supportive but asks no probing or challenging questions, lets several important claims pass unexamined (FDA approval process, US pricing strategy, trial methodology), and spends significant airtime referencing unrelated past episodes rather than advancing the substantive discussion.

“I, I think when, when a, when a podcast, uh, starts this, this, this heavy, it's, it's uh, questions immediately feel not inappropriate. But, um, in perspective, it feels like the, the questions I have just aren't that big of a deal anymore.”

“I've again done 265 episodes. There, there, there was, there's been a few episodes where people have shared uh, really in depth journeys”